Principles of vaccine design: Lessons from natureZEPP, Fred.Vaccine. Supplement. 2010, Vol 28, Num 3, issn 1359-5938, C14-C24Article

Biosimilars in rheumatology: pharmacological and pharmacoeconomic issuesLAPADULA, G; FERRACCIOLI, G. F.Clinical and experimental rheumatology (Testo stampato). 2012, Vol 30, Num 4, issn 0392-856X, S102-S106, SUP73Article

A new approach to the definition of seroconversion following vaccination in a population with high background antibody concentrationsCHANDRAMOHAN, Daniel; COLEMAN, Paul; NELSON, Chris et al.Vaccine. Supplement. 2007, Vol 25, Num 1, issn 1359-5938, A58-A62Article

An immunogenic cathepsin F secreted by the parasitic stages of Teladorsagia circumcinctaREDMOND, D. L; SMITH, S. K; HALLIDAY, A et al.International journal for parasitology. 2006, Vol 36, Num 3, pp 277-286, issn 0020-7519, 10 p.Article

A phase III randomized, controlled study to assess and compare the immunogenicity and tolerability of single and multi-dose vials of DTwP-Hib, a fully liquid quadravalent vaccine and their comparison with TETRAct-Hib vaccine in Indian infants aged 6-14 weeksSHARMA, Hitt; YADAV, Sangita; ASHTAGI, Girija et al.Vaccine. 2011, Vol 29, Num 48, pp 8773-8779, issn 0264-410X, 7 p.Article

Immunogenicity of therapeutic proteins. Part 2: Impact of container closuresSHARMA, Basant.Biotechnology advances. 2007, Vol 25, Num 3, pp 318-324, issn 0734-9750, 7 p.Article

A Survey of Applications of Biological Products for Drug Interference of Immunogenicity AssaysWANG, Yow-Ming C; LANYAN FANG; LIN ZHOU et al.Pharmaceutical research. 2012, Vol 29, Num 12, pp 3384-3392, issn 0724-8741, 9 p.Article

Strategies for the preclinical and clinical characterization of immunogenicityKOREN, E; MYTYCH, D; KOSCEC, M et al.Developments in biologicals. 2005, Vol 122, pp 195-200, issn 1424-6074, 6 p.Conference Paper

AlphalLISA® Assays to Improve the Vaccine Development ProcessCOSENTINO, G.Developments in biologicals. 2012, Vol 134, pp 107-111, issn 1424-6074, 5 p.Conference Paper

An improved method for development of toxoid vaccines and antitoxinsJONES, Russell G. A; LIU, Yvonne; RIGSBY, Peter et al.Journal of immunological methods. 2008, Vol 337, Num 1, pp 42-48, issn 0022-1759, 7 p.Article

Interchangeability, immunogenicity and biosimilarsEBBERS, Hans C; CROW, Stacy A; VULTO, Arnold G et al.Nature biotechnology (Print). 2012, Vol 30, Num 12, pp 1186-1190, issn 1087-0156, 5 p.Article

Statistical considerations for calculation of immunogenicity screening assay cut pointsHOFFMAN, David; BERGER, Marion.Journal of immunological methods. 2011, Vol 373, Num 1-2, pp 200-208, issn 0022-1759, 9 p.Article

Identification and inhibition of drug target interference in immunogenicity assaysZHONG, Zhandong D; DINNOGEN, Steve; HOKOM, Martha et al.Journal of immunological methods. 2010, Vol 355, Num 1-2, pp 21-28, issn 0022-1759, 8 p.Article

Comparison of recombinant and native pertactin of Bordetella pertussisYINGHUA XU; SHUMIN ZHANG; BOLGIANO, Barbara et al.Vaccine. 2011, Vol 29, Num 10, pp 1974-1980, issn 0264-410X, 7 p.Article

Immunological parameters related to the adjuvant effect of the ordered mesoporous silica SBA-15CARVALHO, Luciana V; RUIZ, Rita De C; SCARAMUZZI, Karina et al.Vaccine. 2010, Vol 28, Num 50, pp 7829-7836, issn 0264-410X, 8 p.Article

Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology productsKOREN, Eugen; SMITH, Holly W; PARISH, Thomas et al.Journal of immunological methods. 2008, Vol 333, Num 1-2, pp 1-9, issn 0022-1759, 9 p.Article

Immunogenicity of therapeutic proteins. Part 1: Impact of product handlingSHARMA, Basant.Biotechnology advances. 2007, Vol 25, Num 3, pp 310-317, issn 0734-9750, 8 p.Article

Immunogenicity of biopharmaceuticals. The european perspectiveSCHELLEKENS, H; CASADEVALL, N.Developments in biologicals. 2003, Vol 112, pp 23-28, issn 1424-6074, 6 p.Article

Similar immunogenicity of measles-mumps-rubella (MMR) vaccine administrated at 8 months versus 12 months age in childrenHANQING HE; ENFU CHEN; HAIPING CHEN et al.Vaccine. 2014, Vol 32, Num 31, pp 4001-4005, issn 0264-410X, 5 p.Article

Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccineKEIPP TALBOT, H; KEITEL, Wendy; WALTER, Emmanuel et al.Vaccine. 2008, Vol 26, Num 32, pp 4057-4061, issn 0264-410X, 5 p.Article

Immunogenicity of therapeutic proteins. Part 3: Impact of manufacturing changesSHARMA, Basant.Biotechnology advances. 2007, Vol 25, Num 3, pp 325-331, issn 0734-9750, 7 p.Article

Synthesis, characterization and immunogenicity of silk fibroin-L-asparaginase bioconjugatesZHANG, Yu-Qing; ZHOU, Wei-Lin; SHEN, Wei-De et al.Journal of biotechnology. 2005, Vol 120, Num 3, pp 315-326, issn 0168-1656, 12 p.Article

Biologic fatigue in psoriasisLEVIN, Ethan C; GUPTA, Rishu; BROWN, Gabrielle et al.Journal of dermatological treatment. 2014, Vol 25, Num 1, pp 78-82, issn 0954-6634, 5 p.Article

Preclinical Models Used for Immunogenicity Prediction of Therapeutic ProteinsBRINKS, Vera; WEINBUCH, Daniel; BAKER, Matthew et al.Pharmaceutical research. 2013, Vol 30, Num 7, pp 1719-1728, issn 0724-8741, 10 p.Article

Immunogenicity of Therapeutic Proteins: The Use of Animal ModelsBRINKS, Vera; JISKOOT, Wim; SCHELLEKENS, Huub et al.Pharmaceutical research. 2011, Vol 28, Num 10, pp 2379-2385, issn 0724-8741, 7 p.Article